Weight gain and hair loss during anti-TNF therapy

International Journal of Rheumatology

Volumn 2012, Issue , 2012, Pages

  Lutf, Abdo ^a   Hammoudeh, Mohammed ^a  

^a HAMAD GENERAL HOSPITAL   (Qatar)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; GLUCOCORTICOID; INFLIXIMAB; PREDNISOLONE; TUMOR NECROSIS FACTOR INHIBITOR;

ANKYLOSING SPONDYLITIS; DRUG WITHDRAWAL; FEMALE; HAIR LOSS; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; QUESTIONNAIRE; REVIEW; RHEUMATIC DISEASE; RHEUMATOLOGY; SIDE EFFECT; WEIGHT GAIN;

EID: 84866144658     PISSN: 16879260     EISSN: 16879279     Source Type: Journal    
DOI: 10.1155/2012/593039     Document Type: Review

References (11)

1. Higgins M., D'Agostino R., Kannel W., Cobb J., Benefits and adverse effects of weight loss: observations from the Framingham study. Annals of Internal Medicine 1993 119 7 758 763 2-s2.0-0027434883 (Pubitemid 23313703)
2. Metsios G. S., Stavropoulos-kalinoglou A., Douglas K. M. J., Koutedakis Y., Nevill A. M., Panoulas V. F., Kita M., Kitas G. D., Blockade of tumour necrosis factor- α in rheumatoid arthritis: effects on components of rheumatoid cachexia. Rheumatology 2007 46 12 1824 1827 2-s2.0-36448966421 10.1093/rheumatology/kem291 (Pubitemid 350168299)
3. Alcorn N., Tierney A., Wu O., Gilmour H., Madhok R., Impact of anti-tumour necrosis factor therapy on the weight of patients with rheumatoid arthritis. Annals of the Rheumatic Diseases 2010 69 8, article 1571 2-s2.0-77955458413 10.1136/ard.2009.122424
4. Engvall I. L., Tengstrand B., Brismar K., Hafström I., Infliximab therapy increases body fat mass in early rheumatoid arthritis independently of changes in disease activity and levels of leptin and adiponectin: a randomised study over 21 months. Arthritis Research and Therapy 2010 12 5, article R197 2-s2.0-77958030953 10.1186/ar3169
5. Briot K., Gossec L., Kolta S., Dougados M., Roux C., Prospective assessment of body weight, body composition, and bone density changes in patients with spondyloarthropathy receiving anti-tumor necrosis factor- α treatment. Journal of Rheumatology 2008 35 5 855 861 2-s2.0-44349177615 (Pubitemid 351747128)
6. Ferran M., Calvet J., Almirall M., Pujol R. M., Maymó J., Alopecia areata as another immune-mediated disease developed in patients treated with tumour necrosis factor- α blocker agents. Journal of the European Academy of Dermatology and Venereology 2011 25 4 479 484 2-s2.0-79952369794 10.1111/j.1468-3083.2010.03770.x
7. Le Bidre E., Chaby G., Martin L., Perrussel M., Sassolas B., Sigal M. L., Kaassis C., Lespessailles E., Nseir A., Estve E., Alopecia areata during anti-TNF alpha therapy: nine cases. Annales de Dermatologie et de Venereologie 2011 138 4 285 293 2-s2.0-79954628956 10.1016/j.annder.2011.01.047
8. Maini R., St Clair E. W., Breedveld F., Furst D., Kalden J., Weisman M., Smolen J., Emery P., Harriman G., Feldmann M., Lipsky P., Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. The Lancet 1999 354 9194 1932 1939 2-s2.0-0033524159 10.1016/S0140-6736(99)05246-0
9. Weinblatt M. E., Keystone E. C., Furst D. E., Moreland L. W., Weisman M. H., Birbara C. A., Teoh L. A., Fischkoff S. A., Chartash E. K., Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis and Rheumatism 2003 48 1 35 45 2-s2.0-0037231533 10.1002/art.10697 (Pubitemid 36091645)
10. Bathon J. M., Martin R. W., Fleischmann R. M., A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. The New England Journal of Medicine 2000 343 1586 1593 (Pubitemid 32162981)
11. Ramos-Casals M., Brito-Zerón P., Soto M. J., Cuadrado M. J., Khamashta M. A., Autoimmune diseases induced by TNF-targeted therapies. Best Practice and Research 2008 22 5 847 861 2-s2.0-56349156989 10.1016/j.berh.2008. 09.008